The Spero Project, a local resettlement agency, will host a walk at Scissortail Park to raise money to help refugees in the ...

Spero Therapeutics and partner GSK are stopping a late-stage trial of an experimental oral drug for complicated urinary tract ...

In the last week, the market has been flat, but over the past 12 months, it has risen by 12%, with earnings forecast to grow by 14% annually. While traditional investments often focus on established ...

Spero Therapeutics, Inc. (NASDAQ:SPRO) saw its stock soar by 240% after announcing highly encouraging results from its Phase ...

GSK’s decision to swoop in and save Spero Therapeutics’ antibiotic three years ago appears to have paid off based on a fresh ...

GSK and Spero Therapeutics’ Phase III trial of their oral antibiotic for complicated urinary tract infections (cUTI) will end ...

Spero Therapeutics, Inc. (NASDAQ:SPRO) saw its stock surge by 240% on May 28 following the company’s announcement of the ...

GSK and Spero ended a Phase 3 trial early meeting efficacy goals in cUTIs, positioning its treatment as the first oral ...

Shares of Spero Therapeutics gained after the company and GSK ended their trial for a treatment for complicated urinary tract infections early after it met its primary endpoint. The stock more than ...

Spero and GSK halt a UTI drug trial due to early success; Sanofi plans vaccine production in Vietnam; Brazil investigates ...

Spero Therapeutics (SPRO) stock jumps as GSK (GSK) partnered oral UTI treatment, tebipenem HBr, succeeds in a pivotal Phase 3 ...

Recent health news highlights include GSK and Spero halting a UTI drug trial after achieving success, Sanofi exploring ...